文献速递银屑病与炎症性皮肤病

早期白介素17抑制剂干预可能修饰银屑病病程:回顾性队列研究

Disease modification in psoriasis through early interleukin 17 inhibitor intervention: A retrospective cohort study.
PubMed 文献 · J Am Acad Dermatol · 2025-07-16

该多中心回顾性队列研究纳入2019年4月至2023年4月接受secukinumab或ixekizumab治疗至少4周的中重度斑块状银屑病患者,以停药后1年复发率为主要终点。400例达到PASI 90后停药的患者中位复发时间为3.29个月;141例PASI 90持续超过一年后停药的患者中,超短病程组和短病程组分别有24例(88.89%)和33例(82.5%)实现1年无药缓解。结论认为早期IL-17抑制剂干预可能促进疾病修饰。

要点

  • 达到PASI 90后停药的患者中位复发时间为3.29个月(约14周)。
  • PASI 90持续超过一年后停药者中,病程≤1年组88.89%实现1年无药缓解。
  • 病程≤2年组82.5%实现1年无药缓解,提示早期干预可能修饰病程。

核心结论

  • 早期使用IL-17抑制剂可能促进银屑病疾病修饰并实现长期缓解。

研究设计与样本

  • 多中心回顾性队列研究,纳入2019年4月至2023年4月接受secukinumab或ixekizumab至少4周的中重度斑块状银屑病患者。

主要发现

  • 400例达到PASI 90后停药患者的中位复发时间为3.29个月(约14周)。
  • 141例PASI 90持续超过一年后停药患者中,超短病程组(病程≤1年)24例(88.89%)和短病程组(病程≤2年)33例(82.5%)实现1年无药缓解。

临床怎么用

  • 对中重度斑块状银屑病患者,早期启用IL-17抑制剂可能有助于延长无药缓解。

局限性

  • 本研究未评估早期干预对合并症发展的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although interleukin (IL) 17 inhibitors like secukinumab and ixekizumab have shown significant efficacy in psoriasis, the impact of early intervention with biologics to modify the disease course and achieve long-term remission remains unclear. OBJECTIVES: To examine the potential of early intervention with IL-17 inhibitors for disease modification in psoriasis. METHODS: We conducted a multicenter retrospective cohort study on moderate-to-severe plaque psoriasis patients who received at least 4 weeks of treatment with secukinumab or ixekizumab between April 2019 and April 2023, taking the relapse rate 1 year after cessation of treatment as the primary endpoint. RESULTS: Among 400 patients who discontinued treatment after achieving Psoriasis Area and Severity Index 90, the median relapse time was 3.29 months (approximately 14 weeks). Of 141 patients who discontinued treatment after achieving Psoriasis Area and Severity Index 90 for over a year, 24 (88.89%) in the ultra-short disease duration (psoriasis duration ≤1 year) group and 33 (82.5%) in the short disease duration (psoriasis duration ≤2 years) group achieved 1 year of drug-free remission. LIMITATIONS: The potential impact of early intervention on comorbidity development was not addressed in this study. CONCLUSION: Early intervention with IL-17 inhibitors leads to faster responses and may promote disease modification in psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Chen J, Zhou G, Sha Y, et al. Disease modification in psoriasis through early interleukin 17 inhibitor intervention: A retrospective cohort study. J Am Acad Dermatol. 2025. PMID: 40516878. doi:10.1016/j.jaad.2025.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。